We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after August 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME
Production of a HCMV based vaccine in human amniocyte cell lines
ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME
NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF
COMPOSITIONS AND METHODS FOR TARGETING CONNEXIN HEMICHANNELS
NEW BACTERIOPHAGE ADHESION PROTEINS